Phentermine vs GLP-1: Cost and Effectiveness Compared

Generic phentermine can run under $30 a month with no insurance at all — a small fraction of what any GLP-1 costs before a discount. That price gap is real, and so is the effectiveness gap behind it. Here's what the largest, most current head-to-head evidence actually shows, so the trade-off is a real comparison instead of a guess.

The largest comparative dataset available

A 2026 systematic review and network meta-analysis pooled 262 trials covering 99,791 participants across 19 different obesity medications — the most comprehensive head-to-head dataset comparing older and newer weight-loss drugs published to date¹. A network meta-analysis lets researchers compare drugs that were never tested directly against each other in the same trial, by statistically triangulating through the trials each drug does have, all measured against a common lifestyle-modification baseline.

What the numbers actually show

At one year, versus lifestyle modification alone, the analysis found tirzepatide produced the largest average weight loss at 14.9% (95% CI, 13.9% to 16.0%), followed closely by cagrilintide-semaglutide (CagriSema) at 14.8% (95% CI, 12.7% to 16.9%) — see CagriSema: what the REDEFINE trial data actually show for more on that still-investigational combination. Oral semaglutide came in at 10.9% (95% CI, 9.1% to 12.7%) and subcutaneous semaglutide at 9.8% (95% CI, 9.1% to 10.6%)¹. Phentermine-topiramate — the combination sold as Qsymia, the closest thing to a modern, still-prescribed older-generation option — produced 8.1% average weight loss (95% CI, 6.5% to 9.7%)¹. That's a real, meaningful gap versus the leading GLP-1s (roughly 6-7 percentage points less than tirzepatide), but it's not a rounding error either — phentermine-topiramate still meaningfully outperformed placebo and produced clinically significant weight loss on its own.

What the same data says about tolerability

Effectiveness isn't the only variable that determines whether a drug actually works for you in practice — a drug you can't tolerate long enough to see the benefit doesn't help you, regardless of its trial average. The same analysis found discontinuation due to adverse events ran highest with "orforglipron, naltrexone-bupropion, liraglutide, phentermine-topiramate, CagriSema, and oral semaglutide (risk ratios from 1.9 to 4.2)"¹ — meaning phentermine-topiramate's tolerability profile in this pooled data wasn't meaningfully better than several of the newer drugs, despite its very different mechanism and much lower price. That's a genuinely useful, non-obvious finding: cheaper and older doesn't automatically mean easier to stay on.

Why phentermine still makes sense for some people, and doesn't for others

Phentermine's mechanism (a stimulant that suppresses appetite, chemically related to amphetamines) is entirely different from a GLP-1's incretin-based approach, which means the two aren't purely interchangeable options on a single effectiveness scale — they can suit different situations. Phentermine is typically approved for shorter-term use, isn't recommended for people with cardiovascular disease or uncontrolled hypertension given its stimulant mechanism, and produces a meaningfully smaller average effect. Where it can make sense: as a lower-cost starting point for someone with a smaller amount of weight to lose, as a bridge option while sorting out GLP-1 insurance coverage or cost, or for someone who can't tolerate GLP-1 GI side effects and wants to try a mechanistically different option first. For a larger weight-loss goal, an existing cardiometabolic condition a GLP-1 is specifically approved to treat, or where the added indications covered in GLP-1 and cardiovascular risk: the SELECT trial evidence and GLP-1 and kidney disease: the FLOW trial evidence apply to your health picture, the effectiveness and evidence gap favors a GLP-1 even at a materially higher price.

The actual cost math

Generic phentermine typically runs $15-$40/month cash-pay, versus $150-$500+/month for a legitimate, verified GLP-1 program even before insurance — a genuinely large gap that matters if budget is the binding constraint rather than maximum effectiveness. But the calculation isn't just monthly price against monthly price: a roughly 7-percentage-point larger average weight loss with a GLP-1, sustained over a year or more, is a real difference in outcome that a strict per-dollar comparison misses if it stops at the price tag. The honest framing is that phentermine is the better value for a smaller goal and a tighter budget, and a GLP-1 is the better value for a larger goal or a condition it's specifically evidenced to help — not that one is unconditionally "worth it" and the other isn't.

Where this fits your decision

If cost is the primary constraint, phentermine is a legitimate, FDA-approved, and dramatically cheaper starting point worth discussing with a prescriber — see the cheapest legit way to start GLP-1 for how we think about that budget trade-off more broadly, and how to choose a GLP-1 provider without overpaying for what to look for once you've decided a GLP-1 is the right call. Compare current GLP-1 pricing on our semaglutide and tirzepatide price boards.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.